Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study

Ali Taher, Amal El-Beshlawy, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to

Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalEuropean Journal of Haematology
Volume82
Issue number6
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Thalassemia
Chelating Agents
Iron
Safety
Iron Overload
Liver
Weights and Measures
Chelation Therapy
Organs at Risk
Deferoxamine
Middle East
beta-Thalassemia
deferasirox
Therapeutics

Keywords

  • β-thalassaemia
  • Deferasirox
  • Iron chelation
  • Transfusional iron overload

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia : The ESCALATOR study. / Taher, Ali; El-Beshlawy, Amal; Elalfy, Mohsen S.; Al Zir, Kusai; Daar, Shahina; Habr, Dany; Kriemler-Krahn, Ulrike; Hmissi, Abdel; Al Jefri, Abdullah.

In: European Journal of Haematology, Vol. 82, No. 6, 06.2009, p. 458-465.

Research output: Contribution to journalArticle

Taher, A, El-Beshlawy, A, Elalfy, MS, Al Zir, K, Daar, S, Habr, D, Kriemler-Krahn, U, Hmissi, A & Al Jefri, A 2009, 'Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study', European Journal of Haematology, vol. 82, no. 6, pp. 458-465. https://doi.org/10.1111/j.1600-0609.2009.01228.x
Taher, Ali ; El-Beshlawy, Amal ; Elalfy, Mohsen S. ; Al Zir, Kusai ; Daar, Shahina ; Habr, Dany ; Kriemler-Krahn, Ulrike ; Hmissi, Abdel ; Al Jefri, Abdullah. / Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia : The ESCALATOR study. In: European Journal of Haematology. 2009 ; Vol. 82, No. 6. pp. 458-465.
@article{31892166a5f545e4843894508cb630d9,
title = "Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study",
abstract = "Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to",
keywords = "β-thalassaemia, Deferasirox, Iron chelation, Transfusional iron overload",
author = "Ali Taher and Amal El-Beshlawy and Elalfy, {Mohsen S.} and {Al Zir}, Kusai and Shahina Daar and Dany Habr and Ulrike Kriemler-Krahn and Abdel Hmissi and {Al Jefri}, Abdullah",
year = "2009",
month = "6",
doi = "10.1111/j.1600-0609.2009.01228.x",
language = "English",
volume = "82",
pages = "458--465",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

T2 - The ESCALATOR study

AU - Taher, Ali

AU - El-Beshlawy, Amal

AU - Elalfy, Mohsen S.

AU - Al Zir, Kusai

AU - Daar, Shahina

AU - Habr, Dany

AU - Kriemler-Krahn, Ulrike

AU - Hmissi, Abdel

AU - Al Jefri, Abdullah

PY - 2009/6

Y1 - 2009/6

N2 - Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to

AB - Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to

KW - β-thalassaemia

KW - Deferasirox

KW - Iron chelation

KW - Transfusional iron overload

UR - http://www.scopus.com/inward/record.url?scp=65349152022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349152022&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2009.01228.x

DO - 10.1111/j.1600-0609.2009.01228.x

M3 - Article

C2 - 19187278

AN - SCOPUS:65349152022

VL - 82

SP - 458

EP - 465

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -